ImmuCellICCC
About: ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Employees: 80
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.81% less ownership
Funds ownership: 15.55% [Q2] → 14.74% (-0.81%) [Q3]
21% less funds holding
Funds holding: 28 [Q2] → 22 (-6) [Q3]
27% less capital invested
Capital invested by funds: $5.88M [Q2] → $4.27M (-$1.61M) [Q3]
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Research analyst outlook
We haven’t received any recent analyst ratings for ICCC.
Financial journalist opinion
Based on 3 articles about ICCC published over the past 30 days
